PDCD1 and cancer: Therefore, anti-PD-1/PD-L1 antibodies or PD-1/PD-L1 inhibitors have been tested for their therapeutic response in many cancers, including HNSCC, where two (pembrolizumab, nivolumab) are now FDA approved for recurrent or metastatic disease.